SEC Filing Summary: Movano Inc. (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Movano Inc. (not Corvex, Inc.) on December 17, 2025, reporting events that occurred on December 16, 2025. The filing details the results of a Special Meeting of Stockholders held to approve corporate governance and capital structure amendments.
Key Financial Metrics
This filing is a current report regarding corporate actions and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Corporate Actions
Stockholders approved four key matters at the Special Meeting:
- Equity Issuance Approval: Authorized the issuance of more than 20% of outstanding common stock pursuant to a Purchase Agreement with Chardan Capital Markets, LLC (dated November 6, 2025) to comply with Nasdaq Listing Rule 5635(d). Votes: 252,589 For, 2,088 Against, 2,144 Abstain.
- Authorized Share Increase: Approved amending the Certificate of Incorporation to increase authorized common shares from 500,000,000 to 2,500,000,000. Votes: 500,623 For, 23,285 Against, 2,556 Abstain.
- Incentive Plan Amendment: Approved Amendment No. 3 to the Amended and Restated 2019 Omnibus Incentive Plan. Votes: 241,887 For, 12,456 Against, 2,478 Abstain.
- Meeting Adjournment: Approved the adjournment of the Special Meeting to permit further proxy solicitation if necessary. Votes: 508,070 For, 16,174 Against, 2,220 Abstain.
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or specific risk factors beyond the standard incorporation by reference of the Special Meeting Proxy Statement for details on the Incentive Plan. The company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the terms of the Chardan Capital Markets Purchase Agreement referenced for the equity issuance.
- Review the full text of Amendment No. 3 to the 2019 Omnibus Incentive Plan (Exhibit 10.1) for changes to share limits or vesting terms.
- Confirm the impact of the 5x increase in authorized shares on future dilution potential.
- Check the Special Meeting Proxy Statement (filed November 24, 2025) for detailed rationale behind these proposals.